



HHS Public Access

Author manuscript

J Clin Psychiatry. Author manuscript; available in PMC 2019 March 11.

Published in final edited form as:

J Clin Psychiatry. 2016 October ; 77(10): 1420–1427. doi:10.4088/JCP.14m09440.

Further Evidence for Smoking and Substance Use Disorders in Youth with Bipolar Disorder

Timothy Wilens, M.D.^{1,2}, Joseph Biederman, M.D.^{1,2}, MaryKate Martelon, M.P.H.¹, Courtney Zulauf, B.A.¹, Jesse Anderson, B.A.¹, Amy Yule, M.D.¹, Janet Wozniak, M.D.¹, Ronna Fried, Ph.D.¹, and Stephen Faraone, Ph.D.³

¹Clinical and Research Programs in Pediatric Psychopharmacology and Adult ADHD
Massachusetts General Hospital, Boston, MA 02114

²Department of Psychiatry, Harvard Medical School, Boston, MA 02115

³Department of Psychiatry and of Neuroscience and Physiology, SUNY Upstate Medical
University, Syracuse, NY, 13210

Abstract

Objective: Bipolar disorder (BPD) is a highly morbid disorder increasingly recognized in adolescents. The aim of this study was to examine the risk for substance use disorders (SUDs; alcohol or drug use or dependence) and cigarette smoking in adolescents with BPD.

Methods: We evaluated the risk for SUDs and cigarette smoking in a case control family-based study of adolescents with (n=105, age 13.6 ± 2.5 years) and without (“controls”, n=98, age 13.7 ± 2.1 years) BPD at baseline and at 5 year follow-up (BPD: n=68; controls: n=81; 73% re-ascertainment). Rates of disorders were assessed by blinded structured interviews.

Results: Adolescents growing up with BPD, compared to controls, were more likely to endorse higher rates of SUD (51% vs. 26%; Hazard Ratio (HR) =2.1; 95% Confidence Interval (CI): 1.2, 3.8, p=0.001) and cigarette smoking (51% vs. 17%; HR = 3.2; 95% CI: 1.6, 6.7; p=0.001); as well as earlier-onset of SUD (SUD (14.9 ± 2.6[SD] years vs. 16.5 ± 1.6 years; t=2.6; p=0.01). Subjects with the persistence of a BPD diagnosis were also more likely to endorse cigarette smoking and SUD in comparison to those who lost a BPD diagnosis or controls at follow-up.

Conclusion: The results provide further evidence that adolescents with BPD are at a significantly increased risk to develop cigarette smoking and SUDs when compared to their non-mood disordered peers. These findings indicate that youth with BPD should be carefully monitored for the development of cigarette smoking and SUDs.

Keywords

adolescent; family; bipolar disorder; substance abuse; longitudinal

Address correspondence to: Timothy E. Wilens, M.D., Pediatric Psychopharmacology, Massachusetts General Hospital, 55 Fruit Street, YAW 6A, Boston, MA 02114, Tel: 617-724-5600, FAX: 617-724-3742, twilens@partners.org.

Introduction

A growing literature documents that juvenile bipolar disorder (BPD) is a prevalent, highly morbid condition estimated to affect up to 5% of adolescents^{1, 2}. Longitudinal studies document that the disorder is associated with elevated levels of functional impairments including high rates of psychiatric hospitalization, academic and occupational underachievement, disruption of the family environment, psychosocial disability and comorbid psychiatric disorders³⁻⁶.

Among the most concerning problems in BPD are those associated with the development of cigarette smoking and substance use disorders (SUDs; drug or alcohol abuse or dependence)⁷. For instance, about one-half of referred and community samples of adults with BPD have a lifetime history of SUDs² and excess BPD has been reported in SUD^{8, 9}. Data suggest a heightened risk for SUDs in adults who experienced BPD onset prior to age 18 years^{7, 10, 11}.

The literature also suggests that juvenile BPD is a major risk factor for SUDs¹²⁻¹⁵ and is over-represented in youth with SUDs^{15, 16}. For example, we previously reported that 31% of adolescents with BPD manifest a SUD at a mean age of 14 years compared to only 4% in a matched group of non-mood disordered adolescents ($p < 0.001$).¹² Since the age of onset of BPD precedes that of SUDs^{12, 14, 17}, it has been suggested the direction of risk is from BPD to SUD^{12, 14, 17}.

The current study's main aim was to examine the association between BPD and SUD in developing adolescents. We examined findings from a controlled, five year longitudinal family study of adolescents with and without BPD attending to developmental factors, correlates of BPD, and psychiatric comorbidity. We hypothesized that adolescents with BPD would continue to be at higher risk for SUD than non-mood disordered adolescents, and that the association between BPD and SUD would be independent of psychiatric comorbidity with ADHD and conduct disorder—two conditions known to raise the risk for SUD. Furthermore, we posited that persistence of BPD would be associated with the highest risk for SUD relative to non-persistent cases and controls.

1 Methods

1.1 Subjects

The current analysis is based on the five-year follow-up study, the methods of which are described in detail in the baseline report of this sample¹². We originally ascertained 108 bipolar adolescent probands and 98 non-mood disordered controls. Briefly, at baseline potential subjects were excluded if they had been adopted, if they had major sensorimotor handicaps, autism, inadequate command of the English language, or a Full Scale IQ less than 70. Child assent and parental consent was obtained.

1.2 Assessments

All diagnostic assessments were made using DSM-IV-based semi-structured interviews. Raters were blind to the (re)ascertainment status of the subjects. Psychiatric assessments for

adolescents relied on the DSM-IV Kiddie Schedule for Affective Disorders-Epidemiologic Version (KSADS-E)¹⁸ while for subjects 18 or older the Scheduled Clinical Interview Diagnosis (SCID)¹⁹ was used. For each diagnosis at baseline and follow-up, information was gathered regarding the ages at onset and offset of syndromatic criteria, interval history (follow-up), and treatment history. As reported previously²⁰, for a subject to be diagnosed with BPD, he or she had to meet full DSM-IV criteria for bipolar I or II disorder by both structured and clinical interviews.

Substance use disorders (SUD) included any non-nicotine drug or alcohol abuse or dependence, and was diagnosed based on DSM-IV criteria. To meet for nicotine dependence, subjects under 18 needed to endorse smoking daily, whereas subjects over 18 needed to endorse smoking at least a pack of cigarettes per day. Rates of disorders reported are lifetime prevalence and SUD data reflect moderate to severe impairment.

All cases at baseline and follow-up were presented to board certified child psychiatrists and licensed psychologists. Diagnoses were considered positive only if the disorder was of clinical concern due to the nature of the symptoms, the associated impairment, and the coherence of the clinical picture. Kappa coefficients of agreement were evaluated by having three experienced, board-certified child and adult psychiatrists diagnose subjects from audio taped interview. Based on 500 assessments from interviews of children and adults, the median kappa coefficient was 0.98 and included kappa coefficients for eight individual diagnoses.

1.3 Statistical analysis

The initial sample included 105 BPD probands and their first-degree relatives and 98 controls and their first-degree relatives¹². For this analysis, we merged the initial and follow-up data and computed lifetime rates of disorders and characteristics using the most severe diagnosis, the earliest onsets and the latest offsets unless noted otherwise. We compared demographic and clinical characteristics between cases and controls using t-tests for continuous outcomes, χ^2 tests for binary outcomes and the Wilcoxon Rank sum test for socio-economic status (SES).

The Hollingshead Four-Factor Index was used to assess socioeconomic status (SES). We used Kaplan Meier Curves and Cox proportional hazard models to assess the risk of SUD at follow-up between BPD subjects and control subjects as well as between subjects with persistent BPD and non-persistent BPD. Persistence of BPD was described as full BPD at wave 1 and full or subthreshold BPD criteria at follow-up (*persistent BPD*)⁵. Subjects with BPD at baseline who no longer met criteria for BPD at follow-up were considered *non-persistent BPD*⁵. The age of onset was computed using the earliest age of onset between baseline and follow-up. An alpha-level of 0.05 was used to assert statistical significance; all statistical tests were two-tailed. We calculated all statistics using Stata 12.0²¹.

2 Results

Among the 203 probands enrolled in the study at wave 1, we had follow-up data on 149 (73%) of probands: 68 BPD subjects and 81 control subjects. More BPD subjects were lost to follow-up compared to controls (37 (35%) vs. 17 (17%), $\chi^2=8.3$, $p=0.004$).

2.1 Clinical characteristics

As shown in Table 1, we found no significant differences at follow-up for age or sex between cases and controls. BPD subjects had a lower SES (higher Hollingshead scores) and more parental history of SUD.

2.1.1 Disorders Comorbid with BPD—The BPD group at follow-up had higher lifetime rates of comorbid psychiatric disorders compared to controls. Significant differences were noted for conduct, oppositional defiant, ADHD, and multiple anxiety disorders (Table 1).

2.2 SUD and Cigarette Smoking in Youth with BPD

The BPD probands, compared to controls, had more *new onset* cases of SUD: alcohol abuse (14 (27%) vs. 12 (15%)), alcohol dependence (14 (22%) vs. 4 (5%)), drug abuse (10 (19%) vs. 10 (13%)), drug dependence (13 (24%) vs. 7 (9%)), any SUD (15 (31%) vs. 18 (23%)), and smoking (18 (25%) vs. 11 (14%)).

At the five year follow-up, while adjusting for SES and parental history of SUD, probands with BPD, compared to controls, reported a significantly higher rate of lifetime SUD (35 (51%) vs. 21 (26%), Hazard Ratio (HR)=2.1; 95% Confidence Interval (CI): 1.2, 3.8; $p=0.001$; Figure 1), as well as higher rates of all individual SUD including alcohol abuse (HR: 2.4; 95% CI: 1.2, 4.9; $p=0.01$), alcohol dependence (HR: 5.0; 95% CI: 1.6, 15.7; $p=0.006$), drug abuse (HR: 2.5; 95% CI: 1.2, 5.6; $p=0.02$), drug dependence (HR: 3.1; 95% CI: 1.3, 7.2; $p=0.01$) and smoking (HR: 3.2; 95% CI: 1.6, 6.7; $p=0.001$). Subjects with BPD also had higher rates of an alcohol use disorder (abuse or dependence; HR: 2.6; 95% CI: 1.3, 5.0; $p=0.006$) and drug use disorder (HR: 2.6; 95% CI: 1.3, 5.1; $p=0.007$). Likewise, more BPD probands (38%, $N=26$) had combined alcohol plus drug use disorders (10%, $N=8$; adjusting for SES and parental history of SUD: HR=4.0; 95% CI: 1.6, 9.6; $p=0.001$).

There was more abuse or dependence of cannabis, opiates, cocaine, sedatives, stimulants, hallucinogens, and other drugs (including aspirin and ecstasy) among subjects with BPD compared to controls (any use disorder, adjusting for SES and parental history of SUD: 27 (40%) vs. 11 (14%); Odds Ratio (OR): 3.7; 95% CI: 1.5, 9.0; $p=0.003$). While cannabis was the most commonly abused drug, 13% and 9% of the BPD group had an addiction to opiates or cocaine (see Table 2).

2.2.1 The Effect of Comorbid Disorders on SUD—We repeated our analyses on SUD and nicotine addiction controlling for ADHD and conduct disorder (CD) – two major comorbid disorders found to independently result in SUD²². When we added ADHD to the model with SES and parental SUD, we found a significant effect of BPD status on age-adjusted risk of nicotine dependence (HR: 3.8; 95% CI: 1.7, 9.0; $p=0.002$), alcohol

dependence (HR: 7.3; 95% CI: 2.1, 25.8; $p=0.002$), drug abuse (HR: 4.1; 95% CI: 1.7, 10.2; $p=0.002$), drug dependence (HR: 3.5; 95% CI: 1.4, 9.3; $p=0.01$), and overall SUD (HR: 2.5; 95% CI: 1.2, 5.0; $p=0.01$). We did not find a significant association for alcohol abuse (HR: 2.1; 95% CI: 1.0, 4.4; $p=0.07$). When we added conduct disorder to the model with SES and parental SUD, all associations lost significance (all p values > 0.05).

SUD onset in Youth with BPD—The mean age of onset for any SUD was 15.5 ± 2.4 years and was similar for the individual ages of onset for drug use disorders (15.5 ± 2.4 years) and alcohol use disorders (16.0 ± 2.4 years). In general, BPD subjects had a > 1 year earlier-onset of a SUD compared to controls: any SUD (14.9 ± 2.6 years vs. 16.5 ± 1.6 years; $t=2.6$; $p=0.01$), alcohol use disorders (15.5 ± 2.7 years vs. 17.1 ± 1.4 years; $t=2.2$; $p=0.03$), and any drug use disorders (15.1 ± 2.6 years vs. 16.2 ± 1.6 years; $t=1.4$; $p=0.16$). The mean duration of any SUD was 3.4 ± 3.1 years. We found that BPD subjects manifest a longer duration of SUD relative to controls (4.4 ± 3.2 years vs. 1.6 ± 1.9 years; $p=0.0007$).

SUD and Nicotine Addiction in BPD at Follow-up: Persistent vs. Non-Persistent BPD—Among the 68 subjects with BPD at both baseline and wave 2 assessments, 23 (34%) reported no BPD at follow-up, 9 (13%) reported subthreshold BPD, and 36 (53%) reported having full-BPD. Qualitative analysis of the data suggested that those with persistent BPD had the highest risk for SUD relative to those with non-persistent BPD and controls. Moreover, we found a linear effect of the three groups (controls = 0, non-persistent BPD = 1, persistent BPD = 2) for any SUD (HR: 1.8 (1.3, 2.4), $p<0.001$), and for smoking (HR: 2.1 (1.5, 2.95), $p<0.001$.) However, when stratifying solely by the presence or absence of persistent BPD, we failed to find significant differences between persistent BPD ($N=45$) and non-persistent BPD ($N=23$) in the percentage of any SUD or cigarette smoking (Figure 2, adjusting for SES and parental history of SUD: Non-persistent vs. controls: HR: 1.6; 95% CI: 0.7, 3.5; $p=0.25$; Persistent vs. controls: HR: 2.5; 95% CI: 1.3, 4.6; $p=0.005$; Persistent vs. non-persistent: HR: 1.5; 95% CI: 0.7, 3.2; $p=0.25$). We found similar results for cigarette smoking (Non-persistent vs. controls: HR: 2.1; 95% CI: 0.9, 5.3; $p=0.11$; Persistent vs. controls: HR: 4.1; 95% CI: 1.9, 8.9; $p<0.001$; Persistent vs. non-persistent: HR: 2.0; 95% CI: 0.9, 4.3; $p=0.09$).

BPD Characteristics associated with SUD—To examine what characteristics within BPD are associated with SUD at follow-up, BPD probands with SUD ($N=35$) were compared to BPD probands without SUD ($N=33$) (Table 3). BPD subjects with versus without SUD had more lifetime hospitalizations related to psychiatric or SUD (72% ($N=49$) vs. 4% ($N=3$); $X^2=76.0$, $p<0.0001$). As expected, there were higher rates of lifetime psychopharmacology in all probands with BPD compared to controls, but these percentages did not significantly differ between those with and without SUD. At baseline or during the 5-year follow-up, we did not find any differences in rates of pharmacotherapy or psychotherapy between BPD subjects with and without SUD (all p values >0.05).

We then examined the temporal relationship of BPD and SUD by examining ages of onset of both disorders. A majority of BPD subjects ($N=29$ (83%)) experienced the full syndromatic onset of their BPD prior to SUD, while a minority had the onset within the same year ($N=3$ (9%)) or after the onset of SUD ($N=3$ (9%)). We did not find a significant difference in the

chronology of mania compared to depression in the sample (onset of mania prior to depression in probands with BPD with and without SUD). We also did not find a significant difference in lifetime SUD or cigarette smoking between BPD I and BPD II at baseline (N 's=47, 58, respectively) or follow-up (31, 37; all p values >0.05).

Discussion

The results of this study support our hypotheses that developing adolescents with BPD manifest an increased risk for cigarette smoking and SUDs compared to their non-mood disordered peers. We also found a disturbing trend of more combined and severe SUDs in adolescents with BPD compared to controls. There was a linear trend for risk of cigarette smoking and SUD with persistent $>$ nonpersistent $>$ controls – although both BPD groups continued to be at higher risk than controls. These data punctuate the need for careful monitoring of cigarette smoking and SUD by providers for these highly dysregulated adolescents.

Our findings that adolescent BPD increases the risk for cigarette smoking and SUDs mirror an emerging literature documenting this risk in clinical and epidemiological samples^{14, 23–26}. For instance, Goldstein et al.¹⁷ found that in 12–17 year old adolescents with BPD followed for a mean of 2.7 years, 32% of subjects had their first-onset of SUD, with 76% of the aforementioned group manifesting multiple SUDs. Our data also support findings noted in adult-based studies that provide further evidence linking age at onset of BPD with the risk for SUD^{7, 10, 12, 27–29}. For instance, Lin et al.¹⁰ reported that early onset BPD was associated with a higher risk for SUD compared to later onset BPD.

Given that early-onset BPD is associated with SUD, and early-onset SUD is associated with a more pernicious SUD course and ongoing impairment³⁰, BPD youth are at a very high risk for severe SUD related difficulties in addition to a chronic BPD course^{13, 31}. In support of this notion, Kozloff and colleagues²⁵ noted that individuals with BPD plus SUD were more likely to use mental health services compared to those without this comorbidity. These data highlight the need for careful ongoing screening of cigarette and substance use in adolescents and young adults³² with BPD.

An important finding in the current study was that the higher risk of cigarette smoking and SUD in BPD youth was independent of ADHD²². However, unlike our results at baseline, the risk for SUD did not remain significant in our follow-up BPD sample when controlling for CD, suggesting that the comorbidity with CD mediates this risk. These findings may be confounded by the high risk for CD in BPD in our and other's samples^{5, 6}. Conversely, it may be that CD in BPD is an important variable in linking SUD to BPD³³.

While potentially confounded by treatment effects on “persistence” and limited by statistical power, we found evidence of a linear effect in that subjects with persistent BPD manifest the highest risk (and earliest onset) of cigarette smoking and SUD relative to nonpersistent BPD and controls. However, our data also suggest that even subjects with non-persistent BPD were at elevated risk for SUD relative to controls. Our findings are consistent with a five-year follow-up report by Wozniak et al.⁵ who, using a similar definition of “persistence,”

reported an almost two-fold higher risk for SUD and cigarette smoking in persistent cases. Along the same lines, Lewinsohn et al.³⁴ reported a higher risk for alcohol and drug use in those with full BPD versus subthreshold BPD.

Similar to others, we found that the majority of adolescents (83%) with BPD and SUD experienced the full syndromic onset of their BPD prior to SUD, while a minority had the onset of their BPD after that of SUD^{35–37}. Winokur et al.³⁸, Strakowski et al.^{39, 40}, and Lin et al.¹⁰ have helped elucidate this developmental timing of SUD as it pertains to BPD in adults. Lin et al.¹⁰ showed that early onset BPD precedes and is associated with SUD, and Winokur³⁸ reported that a subgroup of subjects with BPD plus SUD showed evidence of alcoholism secondary to BPD. It is possible to hypothesize that BPD- associated poor judgment, limited self-control, and emotional dysregulation and disinhibition contribute to the high risk for SUD in young adulthood^{32, 41}. In support of this notion, we recently reported a strong relationship between the degree of emotional dysregulation and the risk for SUD in BPD³².

The findings in the current study need to be tempered against methodological limitations. The sample was mostly Caucasian and may not generalize to community or minority samples. Although our sample was large, the subgroup of adolescents in the control group and those with specific disorders was relatively small, limiting our statistical power for some analyses. Our assessments at baseline and five year follow-up relied on retrospective reporting to detail BPD, SUD, and other psychiatric comorbidity, and may have missed important interval data. Lastly, SUD was defined categorically by subjects meeting full DSM criteria for abuse or dependence, and not by urine toxicology screens. Using these definitions, use and misuse of substances as well as subthreshold non-BPD psychopathology or substance abuse was not captured. Further studies should integrate parent, subject self-report, and subject report during structured interview, as well as urine toxicology testing to more accurately identify substance misuse both categorically and dimensionally in youth⁴².

Despite these limitations, the current data adds to a growing literature indicating that pediatric-onset BPD is associated with a highly significant risk for cigarette smoking and early onset SUD. Persistence of the active symptoms of BPD appears related to the risk for cigarette smoking and SUD at follow-up. Since BPD onsets prior to the SUD in the majority of the cases, practitioners following these individuals should treat symptoms of BPD, and continue to carefully monitor for cigarette smoking and the development of SUD.

Acknowledgments

Funding Source:

All phases of this study were supported by an NIH grant RO1 DA12945 and K24 DA016264 to Dr. Timothy Wilens.

Financial Disclosures:

Timothy Wilens: Dr. Timothy Wilens receives or has received grant support from the following sources: NIH(NIDA), and Pfizer. Dr. Timothy Wilens is or has been a consultant for: Euthymics/Neurovance, NIH(NIDA), Theravance and TRIS. Dr. Timothy Wilens has a published book with Guilford Press. *Straight Talk About Psychiatric Medications for Kids*; and co/edited books *ADHD in Children and Adults*, and *Comprehensive Clinical Psychiatry*. Dr. Wilens is Director of the Center for Addiction Medicine at Massachusetts General Hospital. He

serves as a consultant to the US National Football League (ERM Associates), U.S. Minor/Major League Baseball, and Bay Cove Human Services (Clinical Services).

Joseph Biederman: Dr. Joseph Biederman is currently receiving research support from the following sources: The Department of Defense, Ironshore, Vaya Pharma/Enzymotec, and NIH. In 2014, Dr. Biederman received honoraria from the MGH Psychiatry Academy for tuition-funded CME courses. He has a US Patent Application pending (Provisional Number #61/233,686) through MGH corporate licensing, on a method to prevent stimulant abuse. Dr. Biederman received departmental royalties from a copyrighted rating scale used for ADHD diagnoses, paid by Ingenix, Prophase, Shire, Bracket Global Sunovion, and Theravance; these royalties were paid to the Department of Psychiatry at MGH. In 2013, Dr. Biederman received an honorarium from the MGH Psychiatry Academy for a tuition-funded CME course. He received research support from APSARD, EIMindA, McNeil, and Shire. Dr. Biederman received departmental royalties from a copyrighted rating scale used for ADHD diagnoses, paid by Shire and Sunovion; these royalties were paid to the Department of Psychiatry at MGH.

Stephen Faraone: In the past year, Dr. Faraone received income, travel expenses and/or research support from and/or has been on an Advisory Board for Pfizer, Ironshore, Shire, Akili Interactive Labs, CogCubed, Alcobra, VAYA Pharma, Neurovance, Impax, NeuroLifeSciences and research support from the National Institutes of Health (NIH). His institution is seeking a patent for the use of sodium-hydrogen exchange inhibitors in the treatment of ADHD. In previous years, he received consulting fees or was on Advisory Boards or participated in continuing medical education programs sponsored by: Shire, Alcobra, Otsuka, McNeil, Janssen, Novartis, Pfizer and Eli Lilly. Dr. Faraone receives royalties from books published by Guilford Press: *Straight Talk about Your Child's Mental Health* and Oxford University Press: *Schizophrenia: The Facts*.

Amy Yule: Dr. Amy Yule received grant support from the American Academy of Child and Adolescent Psychiatry Pilot Research Award for Junior Faculty supported by Lilly USA, LLC.

Janet Wozniak: In 2013-2014, Janet Wozniak MD has received research support from Merck/Schering-Plough and income from MGH Psychiatry Academy. In the past she has received research support, consultation fees or speaker's fees from: Eli Lilly, Janssen, Johnson and Johnson, McNeil, Pfizer, Shire. She is author of the book, "Is Your Child Bipolar" published May 2008, Bantam Books. In 2013-2014, her spouse received income from Associated Professional Sleep Societies, Cambridge University Press, Gerson Lerman Group, MGH Psychiatry Academy, Summer Street Partners, UCB, Cantor Colburn. In the past, he has received support, consultation fees, royalties or speaker's fees from: Axon Labs, Boehringer-Ingelheim, Cambridge University Press, Covance, Cephalon, Eli Lilly, GlaxoSmithKline, Impax, Jazz Pharmaceuticals, King, Luitpold, Novartis, Neurogen, Novadel Pharma, Pfizer, Sanofi-Aventis, Sepracor, Takeda, UCB (Schwarz) Pharma, UptoDate, Wyeth, Xenoport, Zeo.

MaryKate Martelon, Courtney Zulauf, Jesse Anderson, and Ronna Fried: The authors have no conflict of interest relevant to this article to disclose.

References

1. Youngstrom EA, Birmaher B, Findling RL. Pediatric bipolar disorder: validity, phenomenology, and recommendations for diagnosis. *Bipolar Disord* 2008 2;10(1 Pt 2):194–214. [PubMed: 18199237]
2. Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the national comorbidity survey replication. *Arch Gen Psychiatry* 2007 5;64(5):543–552. [PubMed: 17485606]
3. Axelson D, Birmaher B, Strober M, et al. Phenomenology of children and adolescents with bipolar spectrum disorders. *Arch Gen Psychiatry* 2006 10;63(10):1139–1148. [PubMed: 17015816]
4. Geller B, Tillman R, Bolhofner K, Zimmerman B, Strauss NA, Kaufmann P. Controlled, blindly rated, direct-interview family study of a prepubertal and early-adolescent bipolar I disorder phenotype: morbid risk, age at onset, and comorbidity. *Arch Gen Psychiatry* 2006 10;63(10):1130–1138. [PubMed: 17015815]
5. Wozniak J, Petty CR, Schreck M, Moses A, Faraone SV, Biederman J. High level of persistence of pediatric bipolar-I disorder from childhood onto adolescent years: a four year prospective longitudinal follow-up study. *J Psychiatr Res* 2011 10;45(10):1273–1282. [PubMed: 21683960]
6. Birmaher B, Axelson D. Course and outcome of bipolar spectrum disorder in children and adolescents: a review of the existing literature. *Dev Psychopathol* 2006 Fall;18(4):1023–1035. [PubMed: 17064427]
7. Goldstein BI, Levitt AJ. Further evidence for a developmental subtype of bipolar disorder defined by age at onset: results from the national epidemiologic survey on alcohol and related conditions. *Am J Psychiatry* 2006 9;163(9):1633–1636. [PubMed: 16946191]

8. Rounsaville BJ, Anton SF, Carroll K, Buddle D, Prusoff BA, Gawin F. Psychiatric diagnoses of treatment-seeking cocaine abusers. *Archives of General Psychiatry* 1991;48:43–51. [PubMed: 1984761]
9. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. *JAMA* 1990;264:2511–2518. [PubMed: 2232018]
10. Lin PI, McInnis MG, Potash JB, et al. Clinical correlates and familial aggregation of age at onset in bipolar disorder. *Am J Psychiatry* 2006;163:240–246. [PubMed: 16449477]
11. Perlis R, Miyahara S, Marangell L, et al. Long-Term implications of early onset in bipolar disorder: data from the first 1000 participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD). *Biological Psychiatry* 2004;55(9):875–881. [PubMed: 15110730]
12. Wilens TE, Biederman J, Adamson JJ, et al. Further evidence of an association between adolescent bipolar disorder with smoking and substance use disorders: a controlled study. *Drug Alcohol Depend* 2008 6 1;95(3):188–198. [PubMed: 18343050]
13. Birmaher B, Axelson D, Strober M, et al. Clinical course of children and adolescents with bipolar spectrum disorders. *Arch Gen Psychiatry* 2006 2;63(2):175–183. [PubMed: 16461861]
14. Goldstein BI, Strober MA, Birmaher B, et al. Substance use disorders among adolescents with bipolar spectrum disorders. *Bipolar Disord* 2008 6;10(4):469–478. [PubMed: 18452443]
15. Biederman J, Faraone SV, Hatch M, Mennin D, Taylor A, George P. Conduct disorder with and without mania in a referred sample of ADHD children. *Journal of Affective Disorders* 1997;44(2–3):177–188. [PubMed: 9241578]
16. Weinberg NZ, Glantz MD. Child psychopathology risk factors for drug abuse: Overview. *Journal of Clinical Child Psychology* 1999;28(3):290–297. [PubMed: 10446678]
17. Goldstein BI, Strober M, Axelson D, et al. Predictors of first-onset substance use disorders during the prospective course of bipolar spectrum disorders in adolescents. *J Am Acad Child Adolesc Psychiatry* 2013 10;52(10):1026–1037. [PubMed: 24074469]
18. Ambrosini PJ. Historical development and present status of the schedule for affective disorders and schizophrenia for school-age children (K-SADS). *J Am Acad Child Adolesc Psychiatry* 2000;39(1):49–58. [PubMed: 10638067]
19. Spitzer RL, Williams JB, Gibbon M, First MB. The Structured Clinical Interview for DSM-III-R (SCID). I: History, rationale, and description. *Arch Gen Psychiatry* 1992;49(8):624–629. [PubMed: 1637252]
20. Wilens T, Biederman J, Wozniak J, Gunawardene S, Wong J, Monuteaux M. Can Adults with Attention-Deficit Hyperactivity Disorder be Distinguished from those with Comorbid Bipolar Disorder: Findings from a Sample of Clinically Referred Adults. *Biological Psychiatry* 2003;54(1):1–8. [PubMed: 12842302]
21. Stata Corporation. *Stata User's Guide: Release 9* College Station, TX: Stata Corp LP; 2005.
22. Charach A, Yeung E, Climans T, Lillie E. Childhood attention-deficit/hyperactivity disorder and future substance use disorders: comparative meta-analyses. *J Am Acad Child Adolesc Psychiatry* 2011 1;50(1):9–21. [PubMed: 21156266]
23. Geller B, Tillman R, Bolhofner K, Zimmerman B. Child bipolar I disorder: prospective continuity with adult bipolar I disorder; characteristics of second and third episodes; predictors of 8-year outcome. *Arch Gen Psychiatry* 2008 10;65(10):1125–1133. [PubMed: 18838629]
24. Delbello MP, Hanseman D, Adler CM, Fleck DE, Strakowski SM. Twelve-month outcome of adolescents with bipolar disorder following first hospitalization for a manic or mixed episode. *Am J Psychiatry* 2007 4;164(4):582–590. [PubMed: 17403971]
25. Kozloff N, Cheung AH, Schaffer A, et al. Bipolar disorder among adolescents and young adults: results from an epidemiological sample. *J Affect Disord* 2010 9;125(1–3):350–354. [PubMed: 20226535]
26. Strober M, Schmidt-Lackner S, Freeman R, Bower S, Lampert C, DeAntonio M. Recovery and relapse in adolescents with bipolar affective illness: A five-year naturalistic, prospective follow-up. *Journal of the American Academy of Child and Adolescent Psychiatry* 1995;34(6):724–731. [PubMed: 7608045]

27. Goldstein BI, Bukstein OG. Comorbid substance use disorders among youth with bipolar disorder: opportunities for early identification and prevention. *J Clin Psychiatry* 2010 3;71(3):348–358. [PubMed: 19961811]
28. Perlis RH, Brown E, Baker RW, Nierenberg AA. Clinical features of bipolar depression versus major depressive disorder in large multicenter trials. *Am J Psychiatry* 2006 2;163(2):225–231. [PubMed: 16449475]
29. McElroy S, Altshuler L, Suppes T, et al. Axis I Psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder. *Am J Psych* 2001;158(3):420–426.
30. Brook JS, Adams RE, Balka EB, Johnson E. Early adolescent marijuana use: risks for the transition to young adulthood. *Psychol Med* 2002;32(1):79–91. [PubMed: 11883732]
31. Geller B, Tillman R, Craney JL, Bolhofner K. Four-year prospective outcome and natural history of mania in children with a prepubertal and early adolescent bipolar disorder phenotype. *Arch Gen Psychiatry* 2004 5;61(5):459–467. [PubMed: 15123490]
32. Wilens TE, Martelon M, Anderson JP, Shelley-Abrahamson R, Biederman J. Difficulties in emotional regulation and substance use disorders: A controlled family study of bipolar adolescents. *Drug Alcohol Depend* 2013 2 16.
33. Carlson GA, Bromet EJ, Sievers S. Phenomenology and outcome of subjects with early- and adult-onset psychotic mania. *Am J Psychiatry* 2000;157(2):213–219. [PubMed: 10671389]
34. Lewinsohn PM, Klein DN, Seeley JR. Bipolar disorder during adolescence and young adulthood in a community sample. *Bipolar Disord* 2000 9;2(3 Pt 2):281–293. [PubMed: 11249806]
35. Wilens TE, Biederman J, Abrantes AM, Spencer TJ. Clinical characteristics of psychiatrically referred adolescent outpatients with substance use disorder. *J Am Acad Child Adolesc Psychiatry* 1997 7;36(7):941–947. [PubMed: 9204672]
36. Mezzich AC, Tarter RE, Hsieh Y, Fuhrman A. Substance abuse severity in female adolescents. Association between age at menarche and chronological age. *The American Journal on Addictions* 1992;1:217–221.
37. Stowell R, Estroff TW. Psychiatric disorders in substance-abusing adolescent inpatients: A pilot study. *Journal of the American Academy of Child and Adolescent Psychiatry* 1992;31:1036–1040. [PubMed: 1429401]
38. Winokur G, Coryell W, Akiskal HS, et al. Alcoholism in manic-depressive (bipolar) illness: Familial illness, course of illness, and the primary-secondary distinction. *American Journal of Psychiatry* 1995;152(3):365–372. [PubMed: 7864261]
39. Strakowski S, Tohen M, Stoll A, Faedda G, Goodwin D. Comorbidity in mania at first hospitalization. *American Journal of Psychiatry* 1992;149(4):554–556. [PubMed: 1348163]
40. Strakowski S, Sax K, McElroy S, Keck P, Hawkins J, West S. Course of psychiatric and substance abuse syndromes co-occurring with bipolar disorder after a first psychiatric hospitalization. *Journal of Clinical Psychiatry* 1998;59(9):465–471. [PubMed: 9771817]
41. Tarter RE, Kirisci L, Mezzich A, et al. Neurobehavioral disinhibition in childhood predicts early age at onset of substance use disorder. *Am J Psychiatry* 2003 6;160(6):1078–1085. [PubMed: 12777265]
42. Gignac M, Wilens TE, Biederman J, Kwon A, Mick E, Swezey A. Assessing cannabis use in adolescents and young adults: what do urine screen and parental report tell you? *J Child Adolesc Psychopharmacol* 2005 10;15(5):742–750. [PubMed: 16262591]




Figure 1. Survival Curves for Substance Use and Smoking (N=149)

While adjusting for SES and parental history of SUD, probands with BPD, compared to controls, reported a significantly higher rate of lifetime SUD (35 (51%) vs. 21 (26%), Hazard Ratio (HR)=2.1;95% Confidence Interval (CI):1.2, 3.8; $p = 0.001$). Subject with BPD also had higher rates of alcohol use disorders (abuse or dependence;HR:2.6; 95% CI: 1.3, 5.0; $p = 0.006$), drug use disorders (HR:2.6; 95% CI: 1.3, 5.1; $p = 0.007$) and cigarette smoking (smoking (HR:3.2; 95% CI: 1.6, 6.7; $p = 0.001$).




Figure 2. Substance Use and Cigarette Smoking (N=149)

While adjusting for SES and parental history of SUD, we found that those with persistent BPD had the highest risk for SUD and cigarette smoking compared to those with non-persistent BPD and controls (SUD: Non-persistent vs. controls: HR: 1.6; 95% CI: 0.7, 3.5; $p = 0.25$; persistent vs. controls: HR: 2.5; 95% CI: 1.3, 4.6; $p = 0.005$; persistent vs. non-persistent: HR: 1.5; 95% CI: 0.7, 3.2; $p = 0.25$; Cigarette Smoking: Non-persistent vs. controls: HR: 2.1; 95% CI: 0.9, 5.3; $p = 0.11$; Persistent vs. controls: HR: 4.1; 95% CI: 1.9, 8.9; $p < 0.001$; persistent vs. non-persistent: HR: 2.0; 95% CI: 0.9, 4.9; $p = 0.09$).

Table 1.

Clinical Characteristics and lifetime comorbidities of the follow-up sample: Bipolar Disorder and Controls (N=149)

	Controls (n=81)	BPD (n=68)	Test statistics, p-value
Demographics	<i>Mean ± SD</i>	<i>Mean ± SD</i>	
Age	19.2 ± 2.5	20.1 ± 3.1	t=-2.0, p=0.05
Socioeconomic status	1.9 ± 1.0	2.5 ± 1.1	z=-3.4, p=0.0006
	<i>N (%)</i>	<i>N (%)</i>	
Sex (male)	48 (59)	42 (62)	$\chi^2=1.0$, p=0.76
Parental History of SUD	38 (47)	51 (75)	$\chi^2=12.1$, p<0.001
Comorbidity(ies)			
Multiple Anxiety Disorders	7 (9)	22 (32)	$\chi^2=13.3$, p<0.001
ADHD	16 (20)	52 (76)	$\chi^2=47.9$, p<0.001
Conduct Disorder	12 (15)	43 (63)	$\chi^2=37.2$, p<0.001
Oppositional Defiant Disorder	13 (16)	63 (93)	$\chi^2=86.8$, p<0.001

Table 2.

Specific Drugs of Abuse and Dependence in Bipolar Disorder and Controls (N=149)

	Controls (n=81)	BPD (n=68)	Test statistics, p-value
Drug Type	<i>N</i> (%)	<i>N</i> (%)	
Cannabis	10 (12)	24 (35)	$\chi^2=11.1, p=0.001$
Opiates	2 (2)	9 (13)	$\chi^2=6.3, p=0.01$
Cocaine	1 (1)	6 (9)	$\chi^2=4.8, p=0.047^*$
Sedatives	0 (0)	3 (4)	$\chi^2=3.6, p=0.09^*$
Stimulants	0 (0)	2 (3)	$\chi^2=2.4, p=0.21^*$
Hallucinogens	1 (1)	3 (4)	$\chi^2=1.4, p=0.3^*$
Other (including aspirin and ecstasy)	0 (0)	3 (4)	$\chi^2=3.6, p=0.09^*$

* Exact test was employed

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 3.

Clinical Characteristics and lifetime comorbidities of Individuals with Bipolar Disorder (BPD) without (–) and with (+) Substance Use Disorders

	BPD-SUD (n=33)	BPD + SUD (n=35)	Test statistics, p-value
Demographics	<i>Mean ± SD</i>	<i>Mean ± SD</i>	
Age	18.7 ± 2.9	21.3 ± 2.8	t=–3.8, p=0.0004
Socioeconomic status (SES)	2.3 ± 1.0	2.7 ± 1.2	z=–1.5, p=0.14
	<i>N (%)</i>	<i>N (%)</i>	
Sex (male), %	20 (61)	22 (63)	$\chi^2 = 0.04$, p=0.85
Parental History of SUD	24 (73)	27 (77)	$\chi^2 = 0.18$, p=0.67
Parental History of MDD	23 (72)	30 (86)	$\chi^2 = 1.9$, p=0.16
Parental History of BPD	10 (31)	10 (29)	$\chi^2 = 0.06$, p=0.81
	<i>Mean ± SD</i>	<i>Mean ± SD</i>	
Total BPD Symptom Count	5.8 ± 1.3	6.3 ± 1.2	t=–1.4, p=0.16
BPD Episodes	24.8 ± 39.8	30.6 ± 48.6	t=–0.6, p=0.60
	<i>N (%)</i>	<i>N (%)</i>	
BPD onset in adolescence	5 (15)	9 (26)	$\chi^2 = 1.2$, p=0.3
MDD onset in adolescence	5 (15)	11 (31)	$\chi^2 = 2.5$, p=0.1
Conduct Disorder	5 (15)	19 (54)	$\chi^2 = 17.0$, p<0.001
Oppositional Defiant Disorder	14 (42)	23 (66)	$\chi^2 = 3.71$, p=0.05
	<i>Mean ± SD</i>	<i>Mean ± SD</i>	
IQ	102.4 ± 14.3	102.1 ± 11.2	t=0.09, p=0.92
	<i>N (%)</i>	<i>N (%)</i>	
Repeated a Grade	5 (15)	10 (29)	$\chi^2 = 1.78$, p=0.18
Special Class	22 (67)	21 (60)	$\chi^2 = 0.32$, p=0.57
Extra Help	25 (76)	27 (77)	$\chi^2 = 0.02$, p=0.89

Abbreviations used: MDD=major depressive disorder